SEC Tracker
Get the app

MaxCyte MXCT

MaxCyte (MXCT) filed its Q3 2025 quarterly report (Form 10-Q), providing investors with an update on the company's financial performance and operational activities during the period. The filing highlights MaxCyte's continued progress in its cell engineering technology and services, which are critical to the development of novel cell and gene therapies - an important growth area for the business. Investors will look to this report to assess the company's short-term momentum and long-term prospects.

Form
10-Q
Filed
Importance
Notable

Open in the appGet the appView on EDGAR

Get an email when MaxCyte files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8731 and related industry codes: the same peer list as the financial tables.

  1. NRC Health NRC public float $195M, Jun 30, 2025
  2. Absci ABSI public float $304M, Jun 30, 2025
  3. OmniAb OABI public float $145M, Jun 30, 2025
  4. Neogenomics NEO public float $680M, Jun 30, 2025
  5. Inotiv NOTV public float $71M, Mar 31, 2025, over 18 months old